Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





PlexBio Receives CE Mark for PCR-based Coronavirus Detection Kit

By LabMedica International staff writers
Posted on 05 May 2020
PlexBio Co., Ltd. More...
(Taipei, Taiwan) has received the CE mark for its IntelliPlex SARS-CoV-2 Detection Kit which is now available in European countries.

PlexBio’s PCR-based test detects SARS-CoV-2 in nasopharyngeal swab specimens from patients who may or may not exhibit symptoms of COVID-19. The test runs on the company’s IntelliPlex platform for multiplex assays and can process up to 564 samples within eight hours. The kit leverages the multiplexing capabilities of the IntelliPlex platform by simultaneously detecting the E, N, and RdRp genes in the virus, which mitigates the probability of getting false negative results.

Related Links:
PlexBio Co., Ltd.


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.